Amylyx’s drug is a combination of two molecules that reduce stress and improve energy production in nerve cells, which break down during the disease. The FDA is expected to make its decision on the drug by late June. Patients and their family members testified in favor of the drug in a public hearing. The vote is a recommendation and is not legally binding, the FDA usually agrees with its advisory panels. The drug is currently being tested in a larger study that will eventually include 600 people, topline results are expected in 2024, the company says. It is not clear if the FDA will approve the drug, which is not curative, but it buys time for patients, a physician says. The FDA says the drug does not stop or reverse the disease. . . .
Read more at www.bostonglobe.com